Your browser doesn't support javascript.
loading
Intra- vs. Interhost Evolution of SARS-CoV-2 Driven by Uncorrelated Selection-The Evolution Thwarted.
Hou, Mei; Shi, Jingrong; Gong, Zanke; Wen, Haijun; Lan, Yun; Deng, Xizi; Fan, Qinghong; Li, Jiaojiao; Jiang, Mengling; Tang, Xiaoping; Wu, Chung-I; Li, Feng; Ruan, Yongsen.
Afiliação
  • Hou M; State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
  • Shi J; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Gong Z; State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
  • Wen H; State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
  • Lan Y; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Deng X; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Fan Q; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Li J; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Jiang M; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Tang X; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Wu CI; State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
  • Li F; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Ruan Y; State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
Mol Biol Evol ; 40(9)2023 09 01.
Article em En | MEDLINE | ID: mdl-37707487
In viral evolution, a new mutation has to proliferate within the host (Stage I) in order to be transmitted and then compete in the host population (Stage II). We now analyze the intrahost single nucleotide variants (iSNVs) in a set of 79 SARS-CoV-2 infected patients with most transmissions tracked. Here, every mutation has two measures: 1) iSNV frequency within each individual host in Stage I; 2) occurrence among individuals ranging from 1 (private), 2-78 (public), to 79 (global) occurrences in Stage II. In Stage I, a small fraction of nonsynonymous iSNVs are sufficiently advantageous to rise to a high frequency, often 100%. However, such iSNVs usually fail to become public mutations. Thus, the selective forces in the two stages of evolution are uncorrelated and, possibly, antagonistic. For that reason, successful mutants, including many variants of concern, have to avoid being eliminated in Stage I when they first emerge. As a result, they may not have the transmission advantage to outcompete the dominant strains and, hence, are rare in the host population. Few of them could manage to slowly accumulate advantageous mutations to compete in Stage II. When they do, they would appear suddenly as in each of the six successive waves of SARS-CoV-2 strains. In conclusion, Stage I evolution, the gate-keeper, may contravene the long-term viral evolution and should be heeded in viral studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article